Diagnosis and treatment of CD20 negative B cell lymphomasReport as inadecuate




Diagnosis and treatment of CD20 negative B cell lymphomas - Download this document for free, or read online. Document in PDF available to download.

Biomarker Research

, 5:5

First Online: 07 February 2017Received: 23 December 2016Accepted: 03 February 2017

Abstract

CD20 negative B cell non-Hodgkin lymphoma NHL is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman’s disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.

AbbreviationsCHOPcyclophosphamide, doxorubicin, vincristine, and prednisone

CODOX-M-IVACcyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, cytarabine

EPOCHetoposide, vincristine and doxorubicin along with bolus cyclophosphamide and prednisone

HyperCVADcyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate and cytarabine

MoAbmonoclonal antibody

Download fulltext PDF



Author: Tasleem Katchi - Delong Liu

Source: https://link.springer.com/article/10.1186/s40364-017-0088-5







Related documents